Welcome to LookChem.com Sign In|Join Free

CAS

  • or

50593-73-2

Post Buying Request

50593-73-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

50593-73-2 Usage

General Description

4-Chloro-6-methoxy-2-methylquinoline is a chemical compound with the molecular formula C11H10ClNO. It is a quinoline derivative with a chlorine atom at the 4th position, a methoxy group at the 6th position, and a methyl group at the 2nd position on the quinoline ring. 4-CHLORO-6-METHOXY-2-METHYLQUINOLINE has potential applications in the pharmaceutical industry, where it may be used as a building block for the synthesis of various drugs and biologically active molecules. Its unique structure and functional groups make it a valuable intermediate for the production of pharmaceuticals and other organic compounds. Additionally, it may also possess biological activities that make it a target for further research in medicinal chemistry.

Check Digit Verification of cas no

The CAS Registry Mumber 50593-73-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,0,5,9 and 3 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 50593-73:
(7*5)+(6*0)+(5*5)+(4*9)+(3*3)+(2*7)+(1*3)=122
122 % 10 = 2
So 50593-73-2 is a valid CAS Registry Number.
InChI:InChI=1/C11H10ClNO/c1-7-5-10(12)9-6-8(14-2)3-4-11(9)13-7/h3-6H,1-2H3

50593-73-2Relevant articles and documents

-

Voropaeva,Garbar

, (1970)

-

ANTIMALARIAL COMPOUNDS

-

Page/Page column 26-27, (2020/10/20)

Antimalarial compounds of the formula: in which n is 1 or 2; X is C or N; R1 is a moiety comprising a secondary amine and a tertiary amine joined by a C2 to C4 alkyl chain; and R2 is CF3, F, or H, or an analog, combination, derivative, prodrug, stereoisomer, or pharmaceutically acceptable salt thereof. Pharmaceutical compounds including the antimalarial compounds. Methods of treating or preventing malaria comprising administering an effective amount of the antimalarial compounds.

Myobacterium Tuberculosis-Thioredoxin Reductase Inhibitor as an Antitubercular Agent

-

, (2020/05/06)

The invention relates to Mycobacterium tuberculosis-thioredoxin reductase inhibitors, processes for the preparation thereof, drugs containing said compounds, and the use of said compounds for manufacturing drugs.

Syntheses and evaluation of new Quinoline derivatives for inhibition of hnRNP K in regulating oncogene c-myc transcription

Shu, Bing,Zeng, Ping,Kang, Shuangshuang,Li, Peng-Hui,Hu, Dexuan,Kuang, Guotao,Cao, Jiaojiao,Li, Xiaoya,Zhang, Meiling,An, Lin-Kun,Huang, Zhi-Shu,Li, Ding

, p. 1 - 17 (2019/01/04)

Aberrant overexpression of heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a key feature in oncogenesis and progression of many human cancers. hnRNP K has been found to be a transcriptional activator to up-regulate c-myc gene transcription, a critical proto-oncogene for regulation of cell growth and differentiation. Therefore, down-regulation of c-myc transcription by inhibiting hnRNP K through disrupting its binding to c-myc gene promoter is a potential approach for cancer therapy. In the present study, we synthesized and screened a series of Quinoline derivatives and evaluated their binding affinity for hnRNP K. Among these derivatives, (E)-1-(4-methoxyphenyl)-3-(4-morpholino-6-nitroquinolin-2-yl)prop-2-en-1-one (compound 25) was determined to be the first-reported hnRNP K binding ligand with its KD values of 4.6 and 2.6 μM measured with SPR and MST, respectively. Subsequent evaluation showed that the binding of compound 25 to hnRNP K could disrupt its unfolding of c-myc promoter i-motif, resulting in down-regulation of c-myc transcription. Compound 25 showed a selective anti-proliferative effect on human cancer cell lines with IC50 values ranged from 1.36 to 3.59 μM. Compound 25 exhibited good tumor growth inhibition in a Hela xenograft tumor model, which might be related to its binding with hnRNP K. These findings illustrated that inhibition of DNA-binding protein hnRNP K by compound 25 could be a new and selective strategy of regulating oncogene transcription instead of targeting promoter DNA secondary structures such as G-quadruplexes or i-motifs.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 50593-73-2